Top

Published in:

01-07-2011 | Case report

Simultaneous bilateral subtrochanteric fractures following risedronate therapy

Authors: Mikko T. Ovaska, Tatu J. Mäkinen, Rami Madanat

Published in: Journal of Orthopaedic Science | Issue 4/2011

Excerpt

Bisphosphonates are the most commonly prescribed drugs for the treatment of osteoporosis, and have been shown to be highly effective in reducing the risk of vertebral and hip fractures [1]. The mechanism of action of bisphosphonates is based on the inhibition of osteoclast function and induction of osteoclast apoptosis. In experimental studies, prolonged suppression of bone turnover has been shown to result in accumulation of microdamage and increased bone fragility [2, 3]. …

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR. Effects of continuing or stopping aledronate after 5 years of treatment: the Fracture Intervention Trail Long-term Extension (FLEX): a randomized trail. JAMA. 2006;296:2927–38.PubMedCrossRef

Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524–31.PubMedCrossRef

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–301.PubMedCrossRef

Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91:2556–61.PubMedCrossRef

Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2010;468:1991–6.PubMedCrossRef

Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349–53.PubMedCrossRef

Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–31.PubMedCrossRef

Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobar-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporosis Int. 2009;20:1353–62.CrossRef

Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346–50.PubMedCrossRef

10.

Sayed-Noor AS, Sjöden GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy—a case report. Acta Orthop. 2008;79:565–7.PubMedCrossRef

11.

Sayed-Noor AS, Sjöden GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467:1921–6.PubMedCrossRef

12.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cayley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC. The fracture intervention trial and HORIZON pivotal fracture trail streering committee. N Engl J Med. 2010;362:1761–71.PubMedCrossRef

13.

Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362:1825–7.PubMedCrossRef

14.

Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma. 2010;24:75–81.PubMedCrossRef

15.

Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009;80:413–5.PubMedCrossRef

16.

Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304–6.PubMedCrossRef

17.

Somford MP, Draijer FW, Thomassen BJW, Chavassieux PM, Boivin G, Papapoulus SE. Clinical vignette. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736–40.PubMedCrossRef

18.

Ingle BM, Hay SM, Bottjer HM, Eastell R. Changes in bone mass and bone turnover following distal forearm fracture. Osteoporosis Int. 1999;10:399–407.CrossRef

19.

Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948–52.PubMedCrossRef

20.

Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HAP, Eisman JA, McCloskey EV, Mellstrom D. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893–9.PubMedCrossRef

21.

Aspenberg P. Bisphosphonate-induced fractures: nature strikes back? Acta Orthop. 2008;79:459–60.PubMedCrossRef

Title: Simultaneous bilateral subtrochanteric fractures following risedronate therapy
Authors: Mikko T. Ovaska
Tatu J. Mäkinen
Rami Madanat
Publication date: 01-07-2011
Publisher: Springer Japan
Published in: Journal of Orthopaedic Science / Issue 4/2011
Print ISSN: 0949-2658
Electronic ISSN: 1436-2023
DOI: https://doi.org/10.1007/s00776-011-0058-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Simultaneous bilateral subtrochanteric fractures following risedronate therapy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2011

MRI-detected double low-intensity bands in osteonecrosis of the femoral head

Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis

Promotion of rabbit ligament healing by local delivery of hepatocyte growth factor

Comparison of MRI-based assessment systems for osteoarthritic knees: the irregularity index system and WORMS

Insights on PRAME and osteosarcoma by means of gene expression profiling

Do corticosteroids affect lumbar spinal fusion? A rabbit model using high-dose methylprednisolone